{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-015818","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.385750+00:00","generated_at":"2026-05-16T14:17:35.023934+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL","bullets":["Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.","At 150 µg/kg dose, ORR 85.7% and CR 75.0%.","In primary refractory patients (n=25): ORR 80%, CR 64%.","Of 8 prior CAR-T patients, 6 achieved CR.","Grade 3+ neutropenia (32.7%); manageable safety profile overall."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-015818","json":"https://secwatch.observer/filing/0000950103-25-015818.json","markdown":"https://secwatch.observer/filing/0000950103-25-015818.md","text":"https://secwatch.observer/filing/0000950103-25-015818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/0000950103-25-015818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/dp238449_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:17:35.023934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}